Pegademase Completed Phase 3 Trials for ADA-SCID / Severe Combined Immunodeficiency Syndrome / Adenosine Deaminase Deficiency Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT01420627EZN-2279 in Patients With ADA-SCID